Đang chuẩn bị liên kết để tải về tài liệu:
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor (VEGF) or cytokine and reinforced the clinical benefit of second-line everolimus. | RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma Asian versus non-Asian population subanalysis